High-Dose Atorvastatin for Early Stage Age-Related Macular Degeneration

(DELPHI Trial)

This trial explores whether high-dose atorvastatin, a medication typically used to lower cholesterol, can aid individuals with early-stage age-related macular degeneration (AMD) by improving vision recovery and reducing drusen (fatty deposits under the retina). The focus is on individuals with intermediate AMD, particularly those with numerous drusen in their eyes. Candidates may qualify if diagnosed with intermediate AMD in one or both eyes and are not already taking high-dose atorvastatin. The trial aims to determine if this treatment can slow or improve the progression of AMD. As a Phase 2 trial, the research measures the treatment's effectiveness in an initial, smaller group of participants.

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are taking cyclosporine or have been on high-dose atorvastatin or other statins that your doctor thinks you can't switch from safely.

Research has shown that high doses of atorvastatin, a medication commonly used to lower cholesterol, may help treat age-related macular degeneration (AMD). One study found that patients with high-risk AMD improved when taking 80 mg of atorvastatin, suggesting the treatment might help reduce fat deposits in the eye.

Unlike the standard treatments for age-related macular degeneration (AMD), which primarily focus on managing symptoms and slowing progression with options like anti-VEGF injections, Atorvastatin offers a unique approach. Researchers are excited about Atorvastatin because it is a high-dose cholesterol-lowering drug that might reduce the lipid deposits in the retina, potentially slowing down or even halting the disease's progression. This new angle on targeting lipid metabolism could offer a novel pathway for treating intermediate AMD, distinguishing it from current therapies that focus on different mechanisms.

Research suggests that a high dose of atorvastatin, a type of medication, might benefit people with intermediate age-related macular degeneration (AMD). Studies have shown that taking 80 mg of atorvastatin can reduce drusen, the fatty deposits in the eye associated with AMD. This reduction might also improve vision for some patients. Another study found that high doses of statins, like atorvastatin, were linked to a lower risk of developing AMD over time. While these findings are promising, not all studies agree on the effectiveness of statins for AMD. Participants in this trial will receive high-dose atorvastatin to evaluate its effects on intermediate AMD.¹³⁴⁵⁶